" Treating MS Patients With Lower Extremity Spasticity Using Dysport"

NCT ID: NCT03585569

Last Updated: 2018-07-13

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-05-01
• Study Completion Date: 2020-05-31

Brief Summary

The purpose of this study is to determine whether Dysport® (abobotulinumtoxinA) injections for lower extremity spasticity showed a significant reduction of lower extremity spasticity after being injected with Dysport® (abobotulinumtoxinA) in patients with MS.

Detailed Description

Primary Objective To evaluate the effect of Dysport® (abobotulinumtoxin A) on lower extremity spasticity (soleus, gastrocnemius, lateral gastrocnemius, medial gastrocnemius, flexor digitorum longus, flexor halluces longus, rectus femorus, vastus lateralis, lateral hamstrings, medial hamstrings, adductor magnus, adductor longus, adductor brevis, triceps surae, tibialis posterior or anterior tibialis).

Other Objectives

• To explore the effect of Dysport® on improvement in walking ability in patients with MS
• To explore the effect of Dysport® on quality of (QoL) in patients with MS. Primary Endpoint Absolute change from baseline in Modified Ashworth Scale (MAS) through 20 weeks of treatment.

Other Endpoints

• Change from baseline in MAS scores at Weeks 12, 16, and 20.
• Change from baseline on QoL based on patient reported outcome (PRO) measures on the MSWS-12, MSIS 29, pain scales (0-10 pain scale) the MSSS-88, and the Penn spasm frequency scale through 20 weeks of treatment.
• Change from baseline on the time 25 foot walk (T25FW) test with timed up and go (TUG) through 20 weeks of treatment.
• Change from baseline on expanded disability status scale (EDSS) score at Weeks 12, 16, 20.
• Change from baseline in speed, cadence, general symmetry, propulsion, stride length, T25FW, TUG using GWALK device for gait assessments through 20 weeks.
• Adverse events over 20 weeks
• Serious adverse events over 20 weeks

Conditions

Multiple Sclerosis; Spasticity, Muscle

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Abobotulinumtoxin A

Treating Patients with Multiple Sclerosis with lower extremity spasticity using Dysport (Abobotulinumtoxin A)

Intervention Type: BIOLOGICAL

Other Intervention Names

Dysport

Eligibility Criteria

Inclusion Criteria

1. Male or female with confirmed diagnosis of MS1 over 18 years of age.

2. Patients with a clinically definite diagnosis of MS including patients with relapsing-remitting MS, primary progressive MS, progressive relapsing MS, and secondary progressive MS based on clinical history, physical exam, current or previous brain or spine MRI, CSF analysis will be used to specify the class of MS of the patient.

3. Patients with no prior exposure to any commercial Botulinum toxin or patients that have had previous exposure to commercial Botulimun toxin no less than four months after last injection.

4. Naïve patients having a MAS score ≥1 at baseline in any of the following muscles soleus, gastrocnemius, lateral gastrocnemius, medial gastrocnemius, flexor digitorum longus, flexor halluces longus, rectus femorus, vastus lateralis, lateral hamstrings, medial hamstrings, adductor magnus, adductor longus, adductor brevis.

5. Patients with prior exposure to commercial Botulinum having a MAS ≥1 at baseline in any of the following US Dysport label muscles such as the soleus, gastrocnemius, lateral gastrocnemius, medial gastrocnemius, flexor digitorum longus, flexor halluces longus, or muscles beyond the label such as the rectus femorus, vastus lateralis, lateral hamstrings, medial hamstrings, adductor magnus, adductor longus, adductor brevis, tibialis posterior EDSS score less than 7.0.

6. Penn spasm frequency scale at baseline greater than 2.

7. Functional outcomes such as walking speed T25FW baseline walking speed greater than 0.8.

8. Subjects that have agreed to participate and have signed an informed consent form.

-

Exclusion Criteria

1. Subjects having experienced a relapse within the previous 30 days.

2. Recently initiated treatment on antispasmodic therapy or Ampyra within 30 days of screening.

3. Subjects that have not maintained a steady dose of baclofen or other antispasmodics in the previous 30 days will be excluded.

4. Pregnant or women who intend to become pregnant or breastfeeding women. Women of child bearing potential are required to use oral contraceptives, condoms, intrauterine device (IUD) diaphragm, spermicide, sexual abstinence or vasectomized partner. Female patients using contraception should continue to use contraception 3- 4 months post injection. Women of childbearing potential are defined as any female who has experienced menarche and who is NOT permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause.

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ipsen

INDUSTRY

Sponsor Role: collaborator

Neurology Center of New England P.C.

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Salvatore Q Napoli, MD

Role: PRINCIPAL_INVESTIGATOR

Neurology Center of New England P.C.

Locations

Neurology Center of New England P.C.

Foxborough, Massachusetts, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Sarah Cardoso

Role: CONTACT

sarahc@myneurodr.com

781-551-5812 ext. 101

Facility Contacts

Sarah Cardoso

Role: primary

sarahc@myneurodr.com

781-551-5812 ext. 101

Other Identifiers

SAIRB-17-0093

Identifier Type: -

Identifier Source: org_study_id